Current myasthenia gravis therapies can exacerbate comorbidities or create other complications, said James F. Howard Jr, MD, professor of neurology at the University of North Carolina at Chapel Hill.
Current myasthenia gravis therapies can create other complications, said James F. Howard Jr, MD, professor of neurology at the University of North Carolina at Chapel Hill, former chief of the Neuromuscular Disorders Division, and former James F. Howard Distinguished Professor of Neuromuscular Disease.
Transcript
Can comorbidities in myasthenia gravis be worsened by current therapies such as prednisone, for example?
Yes. I mean, with prednisone, we worry about the development of diabetes, of hypertension, osteopenia and osteoporosis—thinning of the bones, if you will—to say nothing of the mood changes that people experience when they take this drug. Other drugs have the potential to impact the liver, for instance. Others have potential impact on the ability to form blood cells. Not every patient experiences them, and some patients are successfully treated with very minimal side effects. But in the whole, in the majority, these happen to such a degree that we don't like them and we need to find better.
MINT Trial 26-Week Data Show Inebilizumab for gMG Is Effective and Safe
April 1st 2025These are data to week 26 on the monoclonal antibody and antineoplastic agent; data out to week 52 of the MINT trial will be presented in a late-breaking oral session at the upcoming American Academy of Neurology Annual Meeting.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Understanding Primary and Secondary Nonadherence to Chronic Oral Medication
March 28th 2025Medication nonadherence to oral anticoagulants and oral anti–prostate cancer medication has been scrutinized through new research conducted among patients and health care providers and presented by the American Medical Group Association at its 2025 annual meeting, held March 26-29 in Grapevine, Texas.
Read More